Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma

Arghya Ray, PhD, Yan Song, PhD, Deepika Sharma Das, PhD, Vincent Macri, MA, Janice Chen, PhD, Claudia Paba-Praba, Paul G. Richardson, MD, Christopher L. Brooks, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 4463.

https://doi.org/10.1182/blood.V128.22.4463.4463

Published: 2016

Journal Articles

A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism

Arghya Ray, PhD, Deepika Sharma DAS, PhD, Yan Song, PhD, Vincent Macri, MA, Christopher L. Brooks, PhD, Eric K. Rowinsky, MD, Paul G. Richardson, MD, Dharminder Chauhan, PhD, Kenneth C Anderson, MD

Blood (2015) 126 (23): 3000.

https://doi.org/10.1182/blood.V126.23.3000.3000

Published: 2015

Journal Articles

SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis

Arghya Ray, PhD, Deepika Sharma Das, PhD, Durgadevi Ravillah, PhD, Yan Song, PhD, Vincent Macri, Christopher Brooks, PhD, Eric Rowinsky, MD, Paul G. Richardson, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2014) 124 (21): 3441.

https://doi.org/10.1182/blood.V124.21.3441.3441

Published: 2014

Journal Articles

SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance

Arghya Ray, Ph.D, Deepika Sharma Das, Ph.D., Ze Tian, Ph.D, Vincent Macri, Christopher L. Brooks, PhD, Paul G. Richardson, MD, Eric Rowinsky, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 3170.

https://doi.org/10.1182/blood.V122.21.3170.3170

Published: 2013

Journal Articles

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Christopher Brooks, PhD, Vincent Macri, Arnaldo Albini, MD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2013) 122 (21): 4104.

https://doi.org/10.1182/blood.V122.21.4104.4104

Published: 2013

NARROW

SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma

A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism

SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis

SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Email alerts

ASH Publications

American Society of Hematology

SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma

A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism

SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis

SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only